Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Global longitudinal strain before cardiac surgery: Improving feasibility, reproducibility, and variability.

Myhr KA, Pedersen FHG, Kristensen CB, Køber L, Hassager C, Møgelvang R.

Echocardiography. 2019 Nov 8. doi: 10.1111/echo.14529. [Epub ahead of print]

PMID:
31705569
2.

Serum NFL levels should be used to monitor multiple sclerosis evolution - No.

Myhr KM, Torkildsen Ø.

Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891. [Epub ahead of print] No abstract available.

PMID:
31625829
3.

The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS).

Skorve E, Lundervold AJ, Torkildsen Ø, Myhr KM.

Mult Scler Relat Disord. 2019 Sep 21;36:101408. doi: 10.1016/j.msard.2019.101408. [Epub ahead of print]

PMID:
31610403
4.

Validation of the multiple sclerosis diagnosis in the Norwegian Patient Registry.

Benjaminsen E, Myhr KM, Grytten N, Alstadhaug KB.

Brain Behav. 2019 Nov;9(11):e01422. doi: 10.1002/brb3.1422. Epub 2019 Oct 4.

5.

Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.

Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman M, Midgard R, Vatne A, Aarseth JH, Riise T, Torkildsen Ø.

Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244. [Epub ahead of print]

PMID:
31573834
7.

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis.

Varhaug KN, Torkildsen Ø, Myhr KM, Vedeler CA.

Front Neurol. 2019 Apr 5;10:338. doi: 10.3389/fneur.2019.00338. eCollection 2019. Review.

8.

Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.

Bringeland GH, Bader L, Blaser N, Budzinski L, Schulz AR, Mei HE, Myhr KM, Vedeler CA, Gavasso S.

Cytometry A. 2019 Mar;95(3):314-322. doi: 10.1002/cyto.a.23723. Epub 2019 Jan 27.

9.

B cell depletion in the treatment of multiple sclerosis.

Myhr KM, Torkildsen Ø, Lossius A, Bø L, Holmøy T.

Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23. Review.

PMID:
30632834
10.

Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study.

Magalhaes S, Pugliatti M, Riise T, Myhr KM, Ciampi A, Bjornevik K, Wolfson C.

Int J Epidemiol. 2019 Aug 1;48(4):1073-1082. doi: 10.1093/ije/dyy269.

PMID:
30561654
11.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
12.

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

PMID:
30196837
13.

Semi-automated estimation of left ventricular ejection fraction by two-dimensional and three-dimensional echocardiography is feasible, time-efficient, and reproducible.

Myhr KA, Pedersen FHG, Kristensen CB, Visby L, Hassager C, Mogelvang R.

Echocardiography. 2018 Nov;35(11):1795-1805. doi: 10.1111/echo.14112. Epub 2018 Aug 2.

PMID:
30073701
14.

Neurofilaments and 10-year follow-up in multiple sclerosis.

Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E.

Mult Scler. 2018 Sep;24(10):1301-1307. doi: 10.1177/1352458518782005. Epub 2018 Aug 1.

PMID:
30066611
15.

α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.

Bjornevik K, Myhr KM, Beiske A, Bjerve KS, Holmøy T, Hovdal H, Midgard R, Riise T, Wergeland S, Torkildsen Ø.

Mult Scler. 2019 Jun;25(7):987-993. doi: 10.1177/1352458518779925. Epub 2018 Jun 4.

PMID:
29862891
16.

The economic impact of multiple sclerosis to the patients and their families in Norway.

Svendsen B, Grytten N, Bø L, Aarseth H, Smedal T, Myhr KM.

Eur J Health Econ. 2018 Dec;19(9):1243-1257. doi: 10.1007/s10198-018-0971-5. Epub 2018 Apr 21.

PMID:
29680926
17.

Severe multiple sclerosis reactivation after gonadotropin treatment.

Torkildsen Ø, Holmøy T, Myhr KM.

Mult Scler Relat Disord. 2018 May;22:38-40. doi: 10.1016/j.msard.2018.02.031. Epub 2018 Mar 6.

PMID:
29525298
18.

Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations.

Olafsson S, Stridh P, Bos SD, Ingason A, Euesden J, Sulem P, Thorleifsson G, Gustafsson O, Johannesson A, Geirsson AJ, Thorsson AV, Sigurgeirsson B, Ludviksson BR, Olafsson E, Kristjansdottir H, Jonasson JG, Olafsson JH, Orvar KB, Benediktsson R, Bjarnason R, Kristjansdottir S, Gislason T, Valdimarsson T, Mikaelsdottir E, Sigurdsson S, Jonsson S, Rafnar T, Aarsland D, Djurovic S, Fladby T, Knudsen GP, Celius EG, Myhr KM, Grondal G, Steinsson K, Valdimarsson H, Bjornsson S, Bjornsdottir US, Bjornsson ES, Nilsson B, Andreassen OA, Alfredsson L, Hillert J, Kockum IS, Masson G, Thorsteinsdottir U, Gudbjartsson DF, Stefansson H, Hjaltason H, Harbo HF, Olsson T, Jonsdottir I, Stefansson K.

NPJ Genom Med. 2017 Aug 8;2:24. doi: 10.1038/s41525-017-0027-2. eCollection 2017.

19.

Progressive multifocal leukoencephalopathy.

Alstadhaug KB, Myhr KM, Rinaldo CH.

Tidsskr Nor Laegeforen. 2017 Dec 12;137(23-24). doi: 10.4045/tidsskr.16.1092. Print 2017 Dec 12. Review. English, Norwegian.

20.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

21.

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.

Olberg HK, Eide GE, Cox RJ, Jul-Larsen Å, Lartey SL, Vedeler CA, Myhr KM.

Eur J Neurol. 2018 Mar;25(3):527-534. doi: 10.1111/ene.13537. Epub 2018 Jan 6.

PMID:
29205701
22.

Break-out session highlights.

Myhr KM, Mäurer M, Ginés MM, Esposito F, Linker R.

Neurodegener Dis Manag. 2017 Nov;7(6s):45-49. doi: 10.2217/nmt-2017-0042.

PMID:
29143586
23.

The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway.

Benjaminsen E, Myhr KM, Alstadhaug KB.

Seizure. 2017 Nov;52:131-135. doi: 10.1016/j.seizure.2017.09.022. Epub 2017 Oct 6.

24.

An update on cladribine for relapsing-remitting multiple sclerosis.

Holmøy T, Torkildsen Ø, Myhr KM.

Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11. Review.

PMID:
28858531
25.

1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins.

Oveland E, Nystad A, Berven F, Myhr KM, Torkildsen Ø, Wergeland S.

Neurochem Int. 2018 Jan;112:267-277. doi: 10.1016/j.neuint.2017.08.008. Epub 2017 Aug 14.

PMID:
28818673
26.

Point-of-care ultrasonography in Norwegian out-of-hours primary health care.

Myhr K, Sandvik H, Morken T, Hunskaar S.

Scand J Prim Health Care. 2017 Jun;35(2):120-125. doi: 10.1080/02813432.2017.1333307. Epub 2017 Jun 8.

27.

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.

Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625. doi: 10.1136/jnnp-2016-315238. Epub 2017 Apr 1.

28.

Body size and physical exercise, and the risk of multiple sclerosis.

Cortese M, Riise T, Bjørnevik K, Myhr KM; Multiple Sclerosis Conscript Service Database Study Group.

Mult Scler. 2018 Mar;24(3):270-278. doi: 10.1177/1352458517699289. Epub 2017 Mar 13.

PMID:
28287051
29.

Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.

Wesnes K, Myhr KM, Riise T, Cortese M, Pugliatti M, Boström I, Landtblom AM, Wolfson C, Bjørnevik K.

Mult Scler. 2018 Feb;24(2):150-157. doi: 10.1177/1352458517694088. Epub 2017 Feb 1.

PMID:
28273774
30.

Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis.

Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA.

Mitochondrion. 2017 May;34:32-35. doi: 10.1016/j.mito.2016.12.003. Epub 2016 Dec 23.

PMID:
28017684
31.

CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Guldbrandsen A, Farag Y, Kroksveen AC, Oveland E, Lereim RR, Opsahl JA, Myhr KM, Berven FS, Barsnes H.

Mol Cell Proteomics. 2017 Feb;16(2):300-309. doi: 10.1074/mcp.O116.064477. Epub 2016 Nov 27.

32.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

33.

The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis.

Lereim RR, Oveland E, Xiao Y, Torkildsen Ø, Wergeland S, Myhr KM, Sun SC, Berven FS.

J Proteomics Bioinform. 2016 Sep;9(9):209-219. Epub 2016 Sep 12.

34.

In-Depth Cerebrospinal Fluid Quantitative Proteome and Deglycoproteome Analysis: Presenting a Comprehensive Picture of Pathways and Processes Affected by Multiple Sclerosis.

Kroksveen AC, Guldbrandsen A, Vaudel M, Lereim RR, Barsnes H, Myhr KM, Torkildsen Ø, Berven FS.

J Proteome Res. 2017 Jan 6;16(1):179-194. doi: 10.1021/acs.jproteome.6b00659. Epub 2016 Oct 26.

PMID:
27728768
35.

Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.

Bjørnevik K, Riise T, Bostrom I, Casetta I, Cortese M, Granieri E, Holmøy T, Kampman MT, Landtblom AM, Magalhaes S, Pugliatti M, Wolfson C, Myhr KM.

Mult Scler. 2017 Jun;23(7):1018-1024. doi: 10.1177/1352458516671028. Epub 2016 Sep 23.

PMID:
27663872
36.

The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.

Grytten N, Skår AB, Aarseth JH, Assmus J, Farbu E, Lode K, Nyland HI, Smedal T, Myhr KM.

Mult Scler. 2017 Jun;23(7):1008-1017. doi: 10.1177/1352458516667240. Epub 2016 Sep 6.

PMID:
27600114
37.

Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom.

Cortese M, Riise T, Bjørnevik K, Bhan A, Farbu E, Grytten N, Hogenesch I, Midgard R, Smith Simonsen C, Telstad W, Ascherio A, Myhr KM.

Ann Neurol. 2016 Oct;80(4):616-24. doi: 10.1002/ana.24769.

PMID:
27554176
38.

No association of tobacco use and disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen Ø.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 14;3(4):e260. doi: 10.1212/NXI.0000000000000260. eCollection 2016 Aug.

39.

Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.

Bjørnevik K, Riise T, Benjaminsen E, Celius EG, Dahl OP, Kampman MT, Løken-Amsrud KI, Midgard R, Myhr KM, Torkildsen Ø, Vatne A, Grytten N.

Mult Scler. 2017 Feb;23(2):213-219. doi: 10.1177/1352458516646863. Epub 2016 Jul 11.

40.

Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood.

Keshari PK, Harbo HF, Myhr KM, Aarseth JH, Bos SD, Berge T.

BMC Genet. 2016 Apr 14;17:59. doi: 10.1186/s12863-016-0367-4.

41.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

Wergeland S, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmøy T, Riise T, Torkildsen Ø.

Eur J Neurol. 2016 Jun;23(6):1064-70. doi: 10.1111/ene.12986. Epub 2016 Mar 21.

PMID:
26998820
42.

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.

Opsahl JA, Vaudel M, Guldbrandsen A, Aasebø E, Van Pesch V, Franciotta D, Myhr KM, Barsnes H, Berle M, Torkildsen Ø, Kroksveen AC, Berven FS.

Proteomics. 2016 Apr;16(7):1154-65. doi: 10.1002/pmic.201500284.

PMID:
26841090
43.

Country break-out session highlights.

Fazekas F, Gehring K, Gallo P, Lebrun-Frénay C, Moral E, Myhr KM.

Neurodegener Dis Manag. 2015;5(6 Suppl):31-7. doi: 10.2217/nmt.15.58. Review.

PMID:
26611270
44.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Torkildsen Ø, Myhr KM, Bø L.

Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883. Review.

45.

Body mass index influence interferon-beta treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2015 Nov 15;288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26.

PMID:
26531700
46.

Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study.

Goulden R, Riise T, Myhr KM, Pugliatti M, Wolfson C.

Eur J Neurol. 2016 Jan;23(1):168-74. doi: 10.1111/ene.12830. Epub 2015 Oct 16.

PMID:
26475404
47.

Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'.

Grytten N, Torkildsen Ø, Myhr KM.

Acta Neurol Scand. 2015 Nov;132(5):368-9. doi: 10.1111/ane.12488. Epub 2015 Sep 15. No abstract available.

PMID:
26369381
48.

Fingolimod does not enhance cerebellar remyelination in the cuprizone model.

Alme MN, Nystad AE, Bø L, Myhr KM, Vedeler CA, Wergeland S, Torkildsen Ø.

J Neuroimmunol. 2015 Aug 15;285:180-6. doi: 10.1016/j.jneuroim.2015.06.006. Epub 2015 Jun 19.

49.

Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.

Kroksveen AC, Jaffe JD, Aasebø E, Barsnes H, Bjørlykke Y, Franciotta D, Keshishian H, Myhr KM, Opsahl JA, van Pesch V, Teunissen CE, Torkildsen Ø, Ulvik RJ, Vethe H, Carr SA, Berven FS.

Proteomics. 2015 Oct;15(19):3361-9. doi: 10.1002/pmic.201400142. Epub 2015 Sep 8.

PMID:
26152395
50.

Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.

Grytten N, Torkildsen Ø, Myhr KM.

Acta Neurol Scand. 2015;132(199):29-36. doi: 10.1111/ane.12428. Review.

Supplemental Content

Support Center